Loganin alleviates macrophage infiltration and activation by inhibiting the MCP-1/CCR2 axis in diabetic nephropathy

Qiu Du,Ying-Xue Fu,An-Mei Shu,Xing Lv,Yu-Ping Chen,Yu-Yan Gao,Jing Chen,Wei Wang,Gao-Hong Lv,Jin-Fu Lu,Hui-Qin Xu,Ying-xue Fu,An-mei Shu,Yu-ping Chen,Yu-yan Gao,Gao-hong Lv,Jin-fu Lu,Hui-qin Xu
DOI: https://doi.org/10.1016/j.lfs.2020.118808
IF: 6.78
2021-05-01
Life Sciences
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background/aims</h3><p>The theory of inflammation is one of the important theories in the pathogenesis of diabetic nephropathy (DN). We herein aimed to explore whether loganin affected macrophage infiltration and activation upon diabetic nephropathy (DN) by a spontaneous DN mice and a co-culture system of glomerular mesangial cells (GMCs) and macrophage cells (RAW264.7) which was induced by advanced glycation end products (AGEs).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods and key findings</h3><p>Loganin showed remarkable capacity on protecting renal from damage by mitigating diabetic symptoms, improving the histomorphology of the kidney, decreasing the expression of extracellular matrix such as FN, COL-IV and TGF-β, reversing the production of IL-12 and IL-10 and decreasing the number of infiltrating macrophages in the kidney. Moreover, loganin showed markedly effects by suppressing iNOS and CD16/32 expressions (M1 markers), increasing Arg-1 and CD206 expressions (M2 markers), which were the phenotypic transformation of macrophage. These effects may be attributed to the inhibition of the receptor for AGEs (RAGE) /monocyte chemotactic protein-1 (MCP-1)/CC chemokine receptor 2 (CCR2) signaling pathway, with significantly down-regulated expressions of RAGE, MCP-1 and CCR2 by loganin. Loganin further decreased MCP-1 secretion when RAGE was silenced, which means other target was involved in regulating the MCP-1 expression. While loganin combinated with the inhibitor of CCR2 exerted stronger anti-inhibition effects of iNOS expression, suggesting that CCR2 was the target of loganin in regulating the activation of macrophages.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Significance</h3><p>Loganin could ameliorate DN kidney damage by inhibiting macrophage infiltration and activation via the MCP-1/CCR2 signaling pathway in DN.</p>
pharmacology & pharmacy,medicine, research & experimental
What problem does this paper attempt to address?